BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

367 related articles for article (PubMed ID: 19826037)

  • 21. Tamoxifen enhances myoepithelial cell suppression of human breast carcinoma progression in vitro by two different effector mechanisms.
    Shao ZM; Radziszewski WJ; Barsky SH
    Cancer Lett; 2000 Sep; 157(2):133-44. PubMed ID: 10936673
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Downregulation of microRNA-27b-3p enhances tamoxifen resistance in breast cancer by increasing NR5A2 and CREB1 expression.
    Zhu J; Zou Z; Nie P; Kou X; Wu B; Wang S; Song Z; He J
    Cell Death Dis; 2016 Nov; 7(11):e2454. PubMed ID: 27809310
    [TBL] [Abstract][Full Text] [Related]  

  • 23. MiR-190b, the highest up-regulated miRNA in ERα-positive compared to ERα-negative breast tumors, a new biomarker in breast cancers?
    Cizeron-Clairac G; Lallemand F; Vacher S; Lidereau R; Bieche I; Callens C
    BMC Cancer; 2015 Jul; 15():499. PubMed ID: 26141719
    [TBL] [Abstract][Full Text] [Related]  

  • 24. miRNA expression patterns in normal breast tissue and invasive breast cancers of BRCA1 and BRCA2 germ-line mutation carriers.
    Vos S; Vesuna F; Raman V; van Diest PJ; van der Groep P
    Oncotarget; 2015 Oct; 6(31):32115-37. PubMed ID: 26378051
    [TBL] [Abstract][Full Text] [Related]  

  • 25. DNA methylation contributes to deregulation of 12 cancer-associated microRNAs and breast cancer progression.
    Pronina IV; Loginov VI; Burdennyy AM; Fridman MV; Senchenko VN; Kazubskaya TP; Kushlinskii NE; Dmitriev AA; Braga EA
    Gene; 2017 Mar; 604():1-8. PubMed ID: 27998789
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Estrogen regulation in human breast cancer cells of new downstream gene targets involved in estrogen metabolism, cell proliferation and cell transformation.
    Vendrell JA; Magnino F; Danis E; Duchesne MJ; Pinloche S; Pons M; Birnbaum D; Nguyen C; Theillet C; Cohen PA
    J Mol Endocrinol; 2004 Apr; 32(2):397-414. PubMed ID: 15072547
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Identification and validation of oncologic miRNA biomarkers for luminal A-like breast cancer.
    McDermott AM; Miller N; Wall D; Martyn LM; Ball G; Sweeney KJ; Kerin MJ
    PLoS One; 2014; 9(1):e87032. PubMed ID: 24498016
    [TBL] [Abstract][Full Text] [Related]  

  • 28. c-Myc overexpression and endocrine resistance in breast cancer.
    McNeil CM; Sergio CM; Anderson LR; Inman CK; Eggleton SA; Murphy NC; Millar EK; Crea P; Kench JG; Alles MC; Gardiner-Garden M; Ormandy CJ; Butt AJ; Henshall SM; Musgrove EA; Sutherland RL
    J Steroid Biochem Mol Biol; 2006 Dec; 102(1-5):147-55. PubMed ID: 17052904
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Integrated analysis of mRNA and miRNA profiles revealed the role of miR-193 and miR-210 as potential regulatory biomarkers in different molecular subtypes of breast cancer.
    Evangelista AF; Oliveira RJ; O Silva VA; D C Vieira RA; Reis RM; C Marques MM
    BMC Cancer; 2021 Jan; 21(1):76. PubMed ID: 33461524
    [TBL] [Abstract][Full Text] [Related]  

  • 30. miR-191/DAB2 axis regulates the tumorigenicity of estrogen receptor-positive breast cancer.
    Tian X; Zhang Z
    IUBMB Life; 2018 Jan; 70(1):71-80. PubMed ID: 29247596
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Long non-coding RNA UCA1 enhances tamoxifen resistance in breast cancer cells through a miR-18a-HIF1α feedback regulatory loop.
    Li X; Wu Y; Liu A; Tang X
    Tumour Biol; 2016 Nov; 37(11):14733-14743. PubMed ID: 27629141
    [TBL] [Abstract][Full Text] [Related]  

  • 32. MicroRNA 'signature' during estrogen-mediated mammary carcinogenesis and its reversal by ellagic acid intervention.
    Munagala R; Aqil F; Vadhanam MV; Gupta RC
    Cancer Lett; 2013 Oct; 339(2):175-84. PubMed ID: 23791885
    [TBL] [Abstract][Full Text] [Related]  

  • 33. MicroRNA-143 is Associated With Pathological Complete Response and Regulates Multiple Signaling Proteins in Breast Cancer.
    García-Vázquez R; Marchat LA; Ruíz-García E; Astudillo-de la Vega H; Meneses-García A; Arce-Salinas C; Bargallo-Rocha E; Carlos-Reyes Á; López-González JS; Pérez-Plasencia C; Ramos-Payán R; Aguilar-Medina M; López-Camarillo C
    Technol Cancer Res Treat; 2019 Jan; 18():1533033819827309. PubMed ID: 30755102
    [TBL] [Abstract][Full Text] [Related]  

  • 34. miRNA as potential biomarkers of breast cancer in the Lebanese population and in young women: a pilot study.
    Nassar FJ; El Sabban M; Zgheib NK; Tfayli A; Boulos F; Jabbour M; El Saghir NS; Talhouk R; Bazarbachi A; Calin GA; Nasr R
    PLoS One; 2014; 9(9):e107566. PubMed ID: 25232827
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Downregulation of miR-223 Expression Is an Early Event during Mammary Transformation and Confers Resistance to CDK4/6 Inhibitors in Luminal Breast Cancer.
    Citron F; Segatto I; Vinciguerra GLR; Musco L; Russo F; Mungo G; D'Andrea S; Mattevi MC; Perin T; Schiappacassi M; Massarut S; Marchini C; Amici A; Vecchione A; Baldassarre G; Belletti B
    Cancer Res; 2020 Mar; 80(5):1064-1077. PubMed ID: 31862778
    [TBL] [Abstract][Full Text] [Related]  

  • 36. E2F7 overexpression leads to tamoxifen resistance in breast cancer cells by competing with E2F1 at miR-15a/16 promoter.
    Chu J; Zhu Y; Liu Y; Sun L; Lv X; Wu Y; Hu P; Su F; Gong C; Song E; Liu B; Liu Q
    Oncotarget; 2015 Oct; 6(31):31944-57. PubMed ID: 26397135
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Integrated MicroRNA-mRNA Profiling Identifies Oncostatin M as a Marker of Mesenchymal-Like ER-Negative/HER2-Negative Breast Cancer.
    Bottai G; Diao L; Baggerly KA; Paladini L; Győrffy B; Raschioni C; Pusztai L; Calin GA; Santarpia L
    Int J Mol Sci; 2017 Jan; 18(1):. PubMed ID: 28106823
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Harmful effect of ERβ on BCRP-mediated drug resistance and cell proliferation in ERα/PR-negative breast cancer.
    Li W; Jia M; Qin X; Hu J; Zhang X; Zhou G
    FEBS J; 2013 Dec; 280(23):6128-40. PubMed ID: 24103091
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Cyr61, a member of the CCN family, is required for MCF-7 cell proliferation: regulation by 17beta-estradiol and overexpression in human breast cancer.
    Sampath D; Winneker RC; Zhang Z
    Endocrinology; 2001 Jun; 142(6):2540-8. PubMed ID: 11356703
    [TBL] [Abstract][Full Text] [Related]  

  • 40. AC1MMYR2, an inhibitor of dicer-mediated biogenesis of Oncomir miR-21, reverses epithelial-mesenchymal transition and suppresses tumor growth and progression.
    Shi Z; Zhang J; Qian X; Han L; Zhang K; Chen L; Liu J; Ren Y; Yang M; Zhang A; Pu P; Kang C
    Cancer Res; 2013 Sep; 73(17):5519-31. PubMed ID: 23811941
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 19.